<DOC>
	<DOCNO>NCT01612143</DOCNO>
	<brief_summary>This open-label , randomize , single dose , 4-sequence , 4-period crossover study assess relative bioavailability setrobuvir tablet formulation versus reference capsule formulation healthy volunteer . Subjects randomize one four treatment sequence receive 4 single oral dos 200 mg setrobuvir , either tablet capsule formulation without high fat meal , washout period least 14 day treatment .</brief_summary>
	<brief_title>A Relative Bioavailability Study Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female adult , 18 55 year age inclusive Body mass index ( BMI ) 18.0 30.0 kg/m2 Healthy status define absence clinically significant acute chronic condition determine complete medical history physical examination Females childbearing potential male female partner ( ) childbearing potential must agree use 2 form contraception define protocol treatment least 3 month last dose study drug Nonsmokers use &lt; 10 cigarette ( equivalent nicotinecontaining product ) per day Negative result follow screen laboratory test : urine drug screen , urine alcohol screen Willing able consume studyspecified meal day dose Pregnant lactate woman , male female partner pregnant lactate History current alcohol abuse and/or drug addiction &lt; /= 2 year prior enrollment study Participation clinical study within 60 day prior study randomization Positive hepatitis B , hepatitis C HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>